Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jonas Müntze
Observed names:
J Muentze,
J. Muentze,
Müntze, Jonas,
Müntze, Jonas Andres
Institution:
Universitätsklinikum Würzburg
Observed institutions:
German Cancer Research Center,
University of Würzburg,
Universitätsklinikum Würzburg,
Actelion (Switzerland)
ORCID:
0000-0001-7494-159X
Observed ORCID:
0000-0001-7494-159X
OpenAlex ID:
A5089203893
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
2018
·
Jonas Müntze
, Daniel Gensler
, et al.
·
Clinical Pharmacology & Therapeutics
·
99
PDF
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)
2020
·
Malte Lenders
, Peter Nordbeck
, et al.
·
Clinical Pharmacology & Therapeutics
·
73
Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)
2021
·
Malte Lenders
, Peter Nordbeck
, et al.
·
European Heart Journal - Cardiovascular Pharmacotherapy
·
70
Hot topics in Fabry disease
2018
·
Tereza Cairns
, Jonas Müntze
, et al.
·
Postgraduate Medical Journal
·
49
PDF
α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease
2017
·
Daniel Oder
, Dan Liu
, et al.
·
Circulation Cardiovascular Genetics
·
46
Characterization of vertigo and hearing loss in patients with Fabry disease
2018
·
Maria Köping
, Wafaa Shehata-Dieler
, et al.
·
Orphanet Journal of Rare Diseases
·
30
PDF
Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease
2018
·
Dan Liu
, Daniel Oder
, et al.
·
Open Heart
·
30
PDF
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study
2022
·
Jonas Müntze
, Kolja Lau
, et al.
·
Molecular Genetics and Metabolism
·
26
Impella CP Use in Patients with Non-Ischaemic Cardiogenic Shock
2019
·
Octavian Maniuc
, Tim Salinger
, et al.
·
ESC Heart Failure
·
20
PDF
Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy
2018
·
Jonas Müntze
, Tim Salinger
, et al.
·
European Heart Journal
·
19
PDF
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry disease
2017
·
Maria Köping
, Wafaa Shehata-Dieler
, et al.
·
PLoS ONE
·
19
PDF
Value of the CHA2DS2-VASc score and Fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation
2018
·
Dan Liu
, Kai Hu
, et al.
·
Clinical Research in Cardiology
·
15
PDF
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review
2021
·
Daniel Oder
, Jonas Müntze
, et al.
·
Cardiovascular Diagnosis and Therapy
·
11
PDF
Association between Comorbidities and Progression of Transvalvular Pressure Gradients in Patients with Moderate and Severe Aortic Valve Stenosis
2018
·
Tim Salinger
, Kai Hu
, et al.
·
Cardiology Research and Practice
·
6
PDF
Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational study
2018
·
Daniel Oder
, Dan Liu
, et al.
·
Medicine
·
6
Long‐term outcome after surgical repair of a rapid‐grown ischemic ventricular aneurysm causing ventricular tachycardia
2019
·
Daniel Gensler
, Jonas Müntze
, et al.
·
Clinical Case Reports
·
3
PDF
2355Treatment of cardiac manifestations in Fabry disease with the oral drug Migalastat: First 12 months results from a cohort of amenable all-comers
2018
·
J Muentze
, D Gensler
, et al.
·
European Heart Journal
·
3
Contrast-enhanced ultrasound for non-invasive differential diagnosis of unclear left atrial mass
2023
·
Martin Christa
, Jonas Müntze
, et al.
·
The International Journal of Cardiovascular Imaging
·
2
PDF
P6421Role of sudden cardiac death as end-stage complication in Fabry disease cardiomyopathy: Impact of primary and secondary prophylactic ICD therapy on long-term outcome
2017
·
D. Oder
, J. Muentze
, et al.
·
European Heart Journal
·
2
Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
2019
·
Jonas Müntze
, Peter Nordbeck
·
Clinical Pharmacology & Therapeutics
·
1
PDF
Abstract 15863: Impact of Right and Left Ventricular Dysfunction on Mortality in Secondary Mitral Regurgitation Patients Without Surgical and Interventional Treatment
2022
·
Dan Liu
, kai hu
, et al.
·
Circulation
Abstract 15768: Relative Longitudinal Strain Apical Sparing Pattern as a Detrimental Factor of Cardiovascular Outcome After Transcatheter Aortic Valve Replacement
2022
·
Dan Liu
, kai hu
, et al.
·
Circulation
4092Magnetic resonance imaging of Fabry disease cardiomyopathy in patients receiving oral chaperone therapy
2019
·
J Muentze
, D Gensler
, et al.
·
European Heart Journal
P1715Management and outcome in patients with non-ischemic cardiogenic shock and Impella CP use
2019
·
O Maniuc
, T Salinger
, et al.
·
European Heart Journal
Die Biomaterialbank des Kompetenznetz Herzinsuffizienz - Eine Qualitätskontrolle
2019
·
Müntze, Jonas Andres
·
Online Publication Service of Würzburg University (Würzburg University)
PDF
Show more works
View as search
Works count:
31
Citation count:
530
H-index:
12
I10-index:
13
Year
Topic
Type